The decision marks a reversal for Caremark, which last summer became the only major pharmacy benefit manager to exclude Zepbound while continuing to cover rival Novo Nordisks Wegovy
The fix: match your syringe to your dose
Think beyond just water
You cannot reliably distinguish between them by color alone
The purpose of this article is to explore the connection between semaglutide and night sweats, helping readers understand why this might happen, how common it is, and what steps can be taken to manage it
In a recent Phase 2 study presented in June 2025, combining it with semaglutide (the active ingredient in Wegovy) led to remarkable outcomes for participants with obesity: An average weight loss of 22% over 72 weeks (compared to 16% with semaglutide alone) About 93% of that loss coming from fat mass, with minimal impact on lean muscle A 58% drop in visceral fat (versus 36% with semaglutide alone) All achieved without requiring dietary or exercise modifications This stands out because typical weight-loss drugs, like GLP-1 agonists, often result in losing both fat and musclea downside, since muscle boosts metabolism and supports overall health as we age
